ZURICH: Nestle plans to pay US$2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.
"Aimmune has US$261 million in cash and US$134 million in debt. With our prior investment of US$473 million in Aimmune, we'll be making a cash payment of just under US$2 billion," NHS head Greg Behar told Reuters in an interview. Aimmune's Palforzia peanut allergy treatment, which recently gained U.S. approval for children, has sales potential of US$1 billion, Behar said. The deal is expected to add to organic growth in 2021 and to cash earnings by 2022/23.The NHS business was on track to more than double sales by 2022, from 2 billion Swiss francs in 2014, and was expected to close 2020 at 3.3 billion francs, he added.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nestle to buy Aimmune Therapeutics for US$2.6 billionNestle said on Thursday it was offering US$34.50 per share for the remaining 74.4per cent in peanut allergy treatment maker Aimmune Therapeutics ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Nestle pays $2 billion to secure Aimmune's allergy treatmentNestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics , as the Swiss company expands its fast-growing health science business. Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to
Source: YahooSG - 🏆 3. / 71 Read more »
Nestle pays $2 billion to secure Aimmune's allergy treatmentNestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics , as the Swiss company expands its fast-growing health science business. Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to
Source: YahooSG - 🏆 3. / 71 Read more »
Nestle to buy Aimmune Therapeutics for US$2.6 billionNestle said on Thursday it was offering US$34.50 per share for the remaining 74.4per cent in peanut allergy treatment maker Aimmune Therapeutics ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »